Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20782332 | 0.77 | ESR1 (0.45) | ESR1THRATHRBALDH1A1 | |
| SCHEMBL21334880 | 0.76 | ALOX5 (0.32) | ALOX5 | |
| SCHEMBL6436472 | 0.76 | ALOX5 (0.42) | ALOX5CETPKDM4EALDH1A1POLB | |
| SCHEMBL19651767 | 0.74 | — | — | |
| SCHEMBL6438428 | 0.73 | ALOX5 (0.37) | ALOX5CETP | |
| SCHEMBL20233502 | 0.73 | CETP (0.39) | ALOX5CETPKDM4EPOLBSLC1A3 | |
| SCHEMBL152864 | 0.72 | — | — | |
| SCHEMBL10355995 | 0.71 | — | — | |
| SCHEMBL13949570 | 0.71 | HPGD (0.41) | ALOX5HPGDALDH1A1 | |
| SCHEMBL19240323 | 0.71 | CETP (0.41) | ALOX5HPGDCETPSLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-11679093-B2 | 2-naphthimidamides, analogues thereof, and methods of treatment using same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230157999-A1 | PYRANO[4,3-B]INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-05-25 | — | — | US | disclosed |
| US-11618757-B2 | Polycyclic compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2023-04-04 | — | — | US | disclosed |
| US-20230041563-A1 | N-(1,3,4-OXADIAZOL-2-YL)ARYLCARBOXAMIDES OR SALTS THEREOF, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND USES THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-11524955-B2 | 2,4-diamino-pyrimidine compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20220213126-A1 | SMALL MOLECULE AUTOPHAGY INDUCERS FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | JOHN WAYNE CANCER INSTITUTE (US) | 2022-07-07 | — | — | US | disclosed |
| US-10981908-B2 | Aryl hydrocarbon receptor (AHR) modulator compounds | PHENEX PHARMACEUTICALS AG (DE) | 2021-04-20 | — | — | US | disclosed |
| US-20080021060-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | ALMIRALL PRODESFARMA AG | 2008-01-24 | — | — | US | disclosed |
| US-20080021060-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | ALMIRALL PRODESFARMA AG | 2008-01-24 | — | — | US | disclosed |
| US-7312231-B2 | Quinuclidine carbamate derivatives and their use as M3 antagonists | ALMIRALL PRODESFARMA AG (CH) | 2007-12-25 | — | — | US | disclosed |
| US-20070287745-A1 | Laulimalide Analogs and Uses Thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-12-13 | — | — | US | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| US-7244853-B2 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | METHYLGENE, INC. (CA) | 2007-07-05 | — | — | US | disclosed |
| US-7208501-B2 | Quinuclidine carbamate derivatives and their use as M3 antagonists | ALMIRALL PRODESFARMA AG (CH) | 2007-04-24 | — | — | US | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
| US-20040072849-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | ESR1 4482/4885ALOX5 3949/4885HPGD 2680/4885 |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | CNR1, CNR2, GPR119 | ESR1 1581/4885ALOX5 1126/4885HPGD 3112/4885 |
| US-20080021060-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | CHRM3, CHRM2, CHRM1 | ESR1 3053/4885ALOX5 4628/4885HPGD 4155/4885 |
| US-11524955-B2 | 2,4-diamino-pyrimidine compounds and method for making and using the compounds | IRAK4, IRAK1, IRAK3 | ESR1 4520/4885ALOX5 4001/4885HPGD 1778/4885 |
| US-20230041563-A1 | N-(1,3,4-OXADIAZOL-2-YL)ARYLCARBOXAMIDES OR SALTS THEREOF, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND USES THEREOF | CYP2B6, CBR3, CYP2A6 | ESR1 1830/4885ALOX5 2065/4885HPGD 3063/4885 |
| US-20230157999-A1 | PYRANO[4,3-B]INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | ESR1 4753/4885ALOX5 2327/4885HPGD 82/4885 |
| US-20220213126-A1 | SMALL MOLECULE AUTOPHAGY INDUCERS FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | TFEB, SQSTM1, BECN1 | ESR1 3692/4885ALOX5 3840/4885HPGD 2402/4885 |
| US-10981908-B2 | Aryl hydrocarbon receptor (AHR) modulator compounds | AHR, ARNT, NR1H2 | ESR1 270/4885ALOX5 512/4885HPGD 253/4885 |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | ESR1 2025/4885ALOX5 1815/4885HPGD 4632/4885 |
| US-20040072849-A1 | Dioxanes and uses thereof | UTS2R, HDAC5, AMDHD2 | ESR1 2541/4885ALOX5 3963/4885HPGD 1507/4885 |
| US-20070287745-A1 | Laulimalide Analogs and Uses Thereof | LPXN, MLX, ZYX | ESR1 4319/4885ALOX5 1021/4885HPGD 1746/4885 |
| US-11618757-B2 | Polycyclic compound and organic light emitting element comprising same | CRY1, CRY2, PER2 | ESR1 35/4885ALOX5 1317/4885HPGD 3334/4885 |
| US-11679093-B2 | 2-naphthimidamides, analogues thereof, and methods of treatment using same | TMPRSS2, TMPRSS4, TMPRSS15 | ESR1 2813/4885ALOX5 4368/4885HPGD 1396/4885 |
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | HDAC5, HDAC4, HDAC3 | ESR1 1251/4885ALOX5 3595/4885HPGD 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.